Cargando…
Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion
Inhibition of proteases shows therapeutic potential. Our previous studies demonstrated the cardioprotection by the Secretory Leukocyte Protease Inhibitor (SLPI) against myocardial ischaemia/reperfusion (I/R) injury. However, it is unclear whether the cardioprotective effect of SLPI seen in our previ...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138276/ https://www.ncbi.nlm.nih.gov/pubmed/35625725 http://dx.doi.org/10.3390/biomedicines10050988 |
_version_ | 1784714584651726848 |
---|---|
author | Mongkolpathumrat, Podsawee Kijtawornrat, Anusak Suwan, Eukote Unajak, Sasimanas Panya, Aussara Pusadee, Tonapha Kumphune, Sarawut |
author_facet | Mongkolpathumrat, Podsawee Kijtawornrat, Anusak Suwan, Eukote Unajak, Sasimanas Panya, Aussara Pusadee, Tonapha Kumphune, Sarawut |
author_sort | Mongkolpathumrat, Podsawee |
collection | PubMed |
description | Inhibition of proteases shows therapeutic potential. Our previous studies demonstrated the cardioprotection by the Secretory Leukocyte Protease Inhibitor (SLPI) against myocardial ischaemia/reperfusion (I/R) injury. However, it is unclear whether the cardioprotective effect of SLPI seen in our previous works is due to the inhibition of protease enzymes. Several studies demonstrate that the anti-protease independent activity of SLPI could provide therapeutic benefits. Here, we show for the first time that recombinant protein of anti-protease deficient mutant SLPI (L72K, M73G, L74G) (mt-SLPI) could significantly reduce cell death and intracellular reactive oxygen species (ROS) production against an in vitro simulated I/R injury. Furthermore, post-ischaemic treatment of mt-SLPI is found to significantly reduce infarct size and cardiac biomarkers lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) activity, improve cardiac functions, attenuate I/R induced-p38 MAPK phosphorylation, and reduce apoptotic regulatory protein levels, including Bax, cleaved-Caspase-3 and total Capase-8, in rats subjected to an in vivo I/R injury. Additionally, the beneficial effect of mt-SLPI was not significantly different from the wildtype (wt-SLPI). In summary, SLPI could provide cardioprotection without anti-protease activity, which could be more clinically beneficial in terms of providing cardioprotection without interfering with basal serine protease activity. |
format | Online Article Text |
id | pubmed-9138276 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91382762022-05-28 Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion Mongkolpathumrat, Podsawee Kijtawornrat, Anusak Suwan, Eukote Unajak, Sasimanas Panya, Aussara Pusadee, Tonapha Kumphune, Sarawut Biomedicines Article Inhibition of proteases shows therapeutic potential. Our previous studies demonstrated the cardioprotection by the Secretory Leukocyte Protease Inhibitor (SLPI) against myocardial ischaemia/reperfusion (I/R) injury. However, it is unclear whether the cardioprotective effect of SLPI seen in our previous works is due to the inhibition of protease enzymes. Several studies demonstrate that the anti-protease independent activity of SLPI could provide therapeutic benefits. Here, we show for the first time that recombinant protein of anti-protease deficient mutant SLPI (L72K, M73G, L74G) (mt-SLPI) could significantly reduce cell death and intracellular reactive oxygen species (ROS) production against an in vitro simulated I/R injury. Furthermore, post-ischaemic treatment of mt-SLPI is found to significantly reduce infarct size and cardiac biomarkers lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) activity, improve cardiac functions, attenuate I/R induced-p38 MAPK phosphorylation, and reduce apoptotic regulatory protein levels, including Bax, cleaved-Caspase-3 and total Capase-8, in rats subjected to an in vivo I/R injury. Additionally, the beneficial effect of mt-SLPI was not significantly different from the wildtype (wt-SLPI). In summary, SLPI could provide cardioprotection without anti-protease activity, which could be more clinically beneficial in terms of providing cardioprotection without interfering with basal serine protease activity. MDPI 2022-04-25 /pmc/articles/PMC9138276/ /pubmed/35625725 http://dx.doi.org/10.3390/biomedicines10050988 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mongkolpathumrat, Podsawee Kijtawornrat, Anusak Suwan, Eukote Unajak, Sasimanas Panya, Aussara Pusadee, Tonapha Kumphune, Sarawut Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion |
title | Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion |
title_full | Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion |
title_fullStr | Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion |
title_full_unstemmed | Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion |
title_short | Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion |
title_sort | anti-protease activity deficient secretory leukocyte protease inhibitor (slpi) exerts cardioprotective effect against myocardial ischaemia/reperfusion |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138276/ https://www.ncbi.nlm.nih.gov/pubmed/35625725 http://dx.doi.org/10.3390/biomedicines10050988 |
work_keys_str_mv | AT mongkolpathumratpodsawee antiproteaseactivitydeficientsecretoryleukocyteproteaseinhibitorslpiexertscardioprotectiveeffectagainstmyocardialischaemiareperfusion AT kijtawornratanusak antiproteaseactivitydeficientsecretoryleukocyteproteaseinhibitorslpiexertscardioprotectiveeffectagainstmyocardialischaemiareperfusion AT suwaneukote antiproteaseactivitydeficientsecretoryleukocyteproteaseinhibitorslpiexertscardioprotectiveeffectagainstmyocardialischaemiareperfusion AT unajaksasimanas antiproteaseactivitydeficientsecretoryleukocyteproteaseinhibitorslpiexertscardioprotectiveeffectagainstmyocardialischaemiareperfusion AT panyaaussara antiproteaseactivitydeficientsecretoryleukocyteproteaseinhibitorslpiexertscardioprotectiveeffectagainstmyocardialischaemiareperfusion AT pusadeetonapha antiproteaseactivitydeficientsecretoryleukocyteproteaseinhibitorslpiexertscardioprotectiveeffectagainstmyocardialischaemiareperfusion AT kumphunesarawut antiproteaseactivitydeficientsecretoryleukocyteproteaseinhibitorslpiexertscardioprotectiveeffectagainstmyocardialischaemiareperfusion |